Home > Insider Trading > Filing (0001654954-19-001597)

Filing Details

Accession Number:: 0001654954-19-001597
Form Type:: 5
Zero Holdings:: No
Publication Time:: 2019-02-14 21:53:03
Reporting Period:: 2018-12-31

Accepted Time:: 2019-02-14 21:53:03
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1378624	Cellular Biomedicine Group Inc.	CBMG	Biological Products, (No Disgnostic Substances) (2836)	861032927

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1569877	K Andrew Chan	1345 Avenue Of The Americas, Fl. 15 New York NY 10105	Ch Legal Ofr, Corp Dev & Sec	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2018-05-27	106	$17.10	22,894	No	4	F	Direct
Common Stock	Disposition	2018-06-27	106	$19.55	22,788	No	4	F	Direct
Common Stock	Disposition	2018-07-27	106	$20.60	22,682	No	4	F	Direct
Common Stock	Disposition	2018-08-27	106	$20.85	22,576	No	4	F	Direct
Common Stock	Disposition	2018-09-27	154	$22.00	22,422	No	4	F	Direct
Common Stock	Disposition	2018-10-26	168	$12.75	22,254	No	4	S	Direct
Common Stock	Disposition	2018-11-27	178	$18.07	22,076	No	4	S	Direct
Common Stock	Disposition	2018-12-27	178	$17.64	21,898	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	F	Direct
No	4	F	Direct
No	4	F	Direct
No	4	F	Direct
No	4	F	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

As previously reported on the Reporting Person's Form 4 filed on April 3, 2017, the Reporting Person was granted 23,000 restricted stock units ("RSUs") (Grant No. LTIP RSU G5) under the Cellular Biomedicine Group, Inc. 2014 Stock Incentive Plan (the "Plan"), which RSUs vest over a period of four years according to the following schedule: 1/48th per month, with the first installment vested on March 27, 2017.
On May 27, 2018, 479 RSUs vested and were delivered to the Reporting Person. Of the 479 RSUs that were vested and delivered, 106 shares of common stock were withheld (at the closing price of the Company's common stock on the NASDAQ Global Market on Friday, May 25, 2018) to satisfy the tax obligation relating to the vesting of the RSUs pursuant to Section 16b-3(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
On June 27, 2018, 479 RSUs vested and were delivered to the Reporting Person. Of the 479 RSUs that were vested and delivered, 106 shares of common stock were withheld (at the closing price of the Company's common stock on the NASDAQ Global Market on Tuesday, June 26, 2018) to satisfy the tax obligation relating to the vesting of the RSUs pursuant to Section 16b-3(e) under the Exchange Act.
On July 27, 2018, 479 RSUs vested and were delivered to the Reporting Person. Of the 479 RSUs that were vested and delivered, 106 shares of common stock were withheld (at the closing price of the Company's common stock on the NASDAQ Global Market on Thursday, July 26, 2018) to satisfy the tax obligation relating to the vesting of the RSUs pursuant to Section 16b-3(e) under the Exchange Act.
On August 27, 2018, 479 RSUs vested and were delivered to the Reporting Person. Of the 479 RSUs that were vested and delivered, 106 shares of common stock were withheld (at the closing price of the Company's common stock on the NASDAQ Global Market on Friday, August 24, 2018) to satisfy the tax obligation relating to the vesting of the RSUs pursuant to Section 16b-3(e) under the Exchange Act.
On September 27, 2018, 479 RSUs vested and were delivered to the Reporting Person. Of the 479 RSUs that were vested and delivered, 154 shares of common stock were withheld (at the closing price of the Company's common stock on the NASDAQ Global Market on Wednesday, September 26, 2018) to satisfy the tax obligation relating to the vesting of the RSUs pursuant to Section 16b-3(e) under the Exchange Act.
On October 26, 2018, upon vesting of his RSUs, the Reporting Person sold an aggregate of 168 shares of common stock at a per share price of $12.75. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
On November 27, 2018, upon vesting of his RSUs, the Reporting Person sold an aggregate of 178 shares of common stock at a per share price of $18.07. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
On December 27, 2018, upon vesting of his RSUs, the Reporting Person sold an aggregate of 178 shares of common stock at a per share price of $17.64. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
The amount only includes shares of common stock granted as part of the Restricted Stock Units under the Cellular Biomedicine Group, Inc. 2014 Stock Incentive Plan and does not include any other shares of common stock of the issuer owned by the Reporting Person, the ownership of which has been reported in his prior filings pursuant to Section 16 of the Exchange Act.